Researchers have developed a two-step approach using whole exome sequencing to predict whether cancer patients will respond to immunotherapy.  Immunotherapies, such as immune checkpoint inhibitors, have transformed the treatment of advanced cancers. However, these therapies have not worked for everyone. To better predict who will benefit from immunotherapy, scientists have developed various biomarkers that help anticipate immunotherapy treatment response. Several

A study published in the American Journal of Human Genetics has identified that progressive liver, kidney, and heart fibrosis may be related to TULP3 mutations in some patients.   Professor John Sayer, Deputy Dean of Clinical Medicine at Newcastle University, said: “Our finding has a huge implication for better diagnosis and management of kidney and liver disease in some patients. What

Your health risks are often dependent upon your genetics. Assessing a single DNA difference that has a small effect on risk may not be clinically useful. However, when hundreds or thousands of these small risks are added up into a single score, often called a polygenic risk score (PRS), they might offer clinically meaningful information about a person’s disease risk.